A Phase 4 interventional study of Fluconazole and Itraconazole in Pityriasis Versicolor, sponsored by Khyber Teaching Hospital. Recruiting at 1 site in Pakistan. Open to participants aged 18 Years to 50 Years. Per ClinicalTrials.gov, last updated 2025-04-10.
Sponsored by Khyber Teaching Hospital · Phase 4, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
This study compares the efficacy of two drugs, namely flucanazole and itraconazole for the treatment of a common fungal infection of skin.
Pityriasis versicolor is a common fungal infection of the superficial skin layers. Avalible treatment options include topical and systemic drugs. fluconazole and itraconazole are commonly used systemic agents. The aim of this study is to compare the efficacy of the two systemic drugs.
Khyber Teaching Hospital is the lead sponsor of 29 studies on the registry; 19 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Group A consists of patients in whom oral fluconazole is given in dose of 300mg once weekly for 2 weeks.
Drug: Fluconazole
Group B consists of patients in whom oral Itraconazole is given in dose of 100mg Twice for 5 days.
Drug: Itraconazole
Oral fluconazole prescribed to group A
Oral itraconazole prescribed to Group B
Efficacy of Treatment
Efficacy of treatment is defined by absence of scaling by naked eye examination ,absence of yellow or golden scale reflection on woods lamp examination and absence of fungal hyphae on microscopic examination.
Time frame: Upto 8 weeks
Plan to share: No — Patient's confidentiality may be breached.
No publications or documents are linked to this record.
Started Mar 2025 (actual). Primary completion is estimated for Dec 2025, 9 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
No contact was published for this record. The registry link below has the sponsor’s details.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: Fluconazole · Itraconazole
Tinea Versicolor
Khyber Teaching Hospital